It must have enough commercial value to justify the expense. What I don’t understand is why do they have to go through safety again? Does safety have to be proven for each paediatric indication? If so everything is just slower and more expensive. That is booted though and part of why everything in the sector is slow, and takes longer and costs more than it should.. I’m sure the wait will be worth it.
Ann: New Phase I/II Clinical Trial in Children with PANDAS/PANS, page-3
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
